JP2017529332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529332A5 JP2017529332A5 JP2017511200A JP2017511200A JP2017529332A5 JP 2017529332 A5 JP2017529332 A5 JP 2017529332A5 JP 2017511200 A JP2017511200 A JP 2017511200A JP 2017511200 A JP2017511200 A JP 2017511200A JP 2017529332 A5 JP2017529332 A5 JP 2017529332A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- agent according
- thieno
- triazolo
- chlorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 claims 26
- 229940124597 therapeutic agent Drugs 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 15
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 14
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 9
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 8
- 239000007962 solid dispersion Substances 0.000 claims 8
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 5
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 claims 4
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 claims 4
- 230000004927 fusion Effects 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 101001021281 Homo sapiens Protein HEXIM1 Proteins 0.000 claims 3
- 102100036307 Protein HEXIM1 Human genes 0.000 claims 3
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000001105 regulatory effect Effects 0.000 claims 3
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 230000003796 beauty Effects 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 230000008707 rearrangement Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 108091005625 BRD4 Proteins 0.000 claims 1
- 102100033641 Bromodomain-containing protein 2 Human genes 0.000 claims 1
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 claims 1
- 102100039788 GTPase NRas Human genes 0.000 claims 1
- 101000871850 Homo sapiens Bromodomain-containing protein 2 Proteins 0.000 claims 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims 1
- 101001109719 Homo sapiens Nucleophosmin Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102100022678 Nucleophosmin Human genes 0.000 claims 1
- HMKHWYHCDUFAJR-UHFFFAOYSA-N acetamide;dihydrate Chemical compound O.O.CC(N)=O HMKHWYHCDUFAJR-UHFFFAOYSA-N 0.000 claims 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 1
- -1 compounds acetamide dihydrate Chemical class 0.000 claims 1
- 230000009477 glass transition Effects 0.000 claims 1
- 108010006693 promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462043063P | 2014-08-28 | 2014-08-28 | |
| US62/043,063 | 2014-08-28 | ||
| PCT/EP2015/069754 WO2016030509A1 (en) | 2014-08-28 | 2015-08-28 | Methods of treating acute myeloid leukemia or acute lymphoid leukemia using pharmaceutical compositions containing thienotriazolodiazepine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017529332A JP2017529332A (ja) | 2017-10-05 |
| JP2017529332A5 true JP2017529332A5 (show.php) | 2018-10-11 |
Family
ID=54012215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511200A Withdrawn JP2017529332A (ja) | 2014-08-28 | 2015-08-28 | チエノトリアゾロジアゼピン化合物を含む医薬組成物を用いる急性骨髄性白血病又は急性リンパ性白血病の治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20170281642A1 (show.php) |
| EP (1) | EP3185871A1 (show.php) |
| JP (1) | JP2017529332A (show.php) |
| KR (1) | KR20170044172A (show.php) |
| CN (1) | CN107427524A (show.php) |
| WO (1) | WO2016030509A1 (show.php) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2947601A1 (en) * | 2014-05-02 | 2015-11-05 | Oncoethix Gmbh | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds |
| EP3365335B1 (en) | 2015-10-23 | 2024-02-14 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases |
| MX395539B (es) | 2016-07-29 | 2025-03-25 | Oncternal Therapeutics Inc | Usos de compuestos de indolinona |
| EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| EP3898615A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| US20220251105A1 (en) * | 2019-05-17 | 2022-08-11 | Celgene Car Llc | Methods of treating a mk2-mediated disorder |
| US20230115945A1 (en) | 2019-12-30 | 2023-04-13 | Tyra Biosciences, Inc. | Aminopyrimidine compounds |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| KR102325607B1 (ko) * | 2020-02-20 | 2021-11-12 | 한국과학기술원 | Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조퓨란-피라졸 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물 |
| WO2021188695A1 (en) * | 2020-03-18 | 2021-09-23 | Metacrine, Inc. | Formulations of a farnesoid x receptor agonist |
| MX2023007793A (es) | 2020-12-30 | 2023-09-22 | Tyra Biosciences Inc | Compuestos de indazol como inhibidores de cinasas. |
| MX2023009954A (es) | 2021-02-26 | 2023-11-09 | Tyra Biosciences Inc | Compuestos de aminopirimidina y métodos de uso de estos. |
| WO2024006897A1 (en) | 2022-06-29 | 2024-01-04 | Tyra Biosciences, Inc. | Indazole compounds |
| EP4547670A1 (en) | 2022-06-29 | 2025-05-07 | Tyra Biosciences, Inc. | Polymorphic compounds and uses thereof |
| WO2024138112A1 (en) | 2022-12-22 | 2024-06-27 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2025129014A1 (en) | 2023-12-15 | 2025-06-19 | Tyra Biosciences, Inc. | Indazole compounds for the treatment of cancer |
| WO2025222097A1 (en) | 2024-04-19 | 2025-10-23 | Tyra Biosciences, Inc. | Indazole-based protac degraders and their anticancer activity |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2412776C (en) * | 2000-06-16 | 2011-03-15 | Mitsubishi Pharma Corporation | Compositions controlling release ph range and/or speed |
| JP5478262B2 (ja) * | 2007-12-28 | 2014-04-23 | 田辺三菱製薬株式会社 | 抗癌剤 |
| EP2569434B1 (en) * | 2010-05-14 | 2019-09-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia and related disorders |
| CN104311562B (zh) * | 2010-05-14 | 2017-07-04 | 达那-法伯癌症研究所 | 用于治疗瘤形成、炎性疾病和其他失调的组合物和方法 |
| DE102011082013A1 (de) * | 2011-09-01 | 2013-03-07 | Bayer Pharma AG | 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine |
| BR112015006537A2 (pt) * | 2012-09-28 | 2017-07-04 | Oncoethix Sa | dispersão sólida, formulação farmacêutica, cápsula farmacêutica, e, tablete farmacêutico |
| US9795612B2 (en) * | 2013-08-01 | 2017-10-24 | Merck Sharp & Dohme Corp. | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
| US9757385B2 (en) * | 2013-11-27 | 2017-09-12 | Merck Sharp & Dohme Corp. | Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds |
-
2015
- 2015-08-28 CN CN201580046616.5A patent/CN107427524A/zh active Pending
- 2015-08-28 US US15/507,496 patent/US20170281642A1/en not_active Abandoned
- 2015-08-28 KR KR1020177007647A patent/KR20170044172A/ko not_active Withdrawn
- 2015-08-28 JP JP2017511200A patent/JP2017529332A/ja not_active Withdrawn
- 2015-08-28 WO PCT/EP2015/069754 patent/WO2016030509A1/en not_active Ceased
- 2015-08-28 EP EP15756648.0A patent/EP3185871A1/en not_active Withdrawn